PT  - JOURNAL ARTICLE
AU  - Jihye Kim
AU  - Ju Yeon Kim
AU  - Jeong-Hoon Lee
AU  - Dong Hyun Sinn
AU  - Moon Haeng Hur
AU  - Ji Hoon Hong
AU  - Min Kyung Park
AU  - Hee Jin Cho
AU  - Na Ryung Choi
AU  - Yun Bin Lee
AU  - Eun Ju Cho
AU  - Su Jong Yu
AU  - Yoon Jun Kim
AU  - Jin Chul Paeng
AU  - Hyo Cheol Kim
AU  - Nam-Joon Yi
AU  - Kwang-Woong Lee
AU  - Kyung-Suk Suh
AU  - Dongho Hyun
AU  - Jong Man Kim
AU  - Jung-Hwan Yoon
TI  - Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection
AID  - 10.2967/jnumed.121.263147
DP  - 2022 Aug 01
TA  - Journal of Nuclear Medicine
PG  - 1215--1222
VI  - 63
IP  - 8
4099  - http://jnm.snmjournals.org/content/63/8/1215.short
4100  - http://jnm.snmjournals.org/content/63/8/1215.full
SO  - J Nucl Med2022 Aug 01; 63
AB  - The surgical treatment for large hepatocellular carcinoma (HCC) remains controversial because of a high risk of recurrence after resection. This study aimed to compare long-term outcomes of transarterial radioembolization (TARE) with resection for patients with large HCC. Methods: This retrospective cohort study included 557 patients who were initially treated with either resection (n = 500) or TARE (n = 57) for large (≥5 cm), single nodular HCC at 2 tertiary centers in Korea. Patients with major portal vein tumor thrombosis or extrahepatic metastasis were excluded. The primary endpoint was overall survival (OS), and secondary endpoints were time to progression (TTP), time to intrahepatic progression (TTIP), and safety. Results: The resection group was younger (median, 60 vs. 69 y) and had a smaller tumor size (median, 7.0 vs. 10.0 cm) (all P < 0.05). After baseline characteristics were balanced using inverse-probability-of-treatment weighting, the OS (hazard ratio [HR], 0.98; 95% CI, 0.40–2.43; P = 0.97), TTP (HR, 1.10; 95% CI, 0.55–2.20; P = 0.80), and TTIP (HR, 1.45; 95% CI, 0.72–2.93; P = 0.30) of the TARE group was comparable to the resection group. TARE was not an independent risk for OS (adjusted HR, 1.04; 95% CI, 0.42–2.59; P = 0.93), TTP (adjusted HR, 0.98; 95% CI, 0.50–1.95; P = 0.96), or TTIP (adjusted HR, 1.30; 95% CI, 0.65–2.58; P = 0.46). The TARE group had a shorter hospital stay and fewer adverse events than the resection group. Conclusion: Compared with surgical resection for large single nodular HCC, TARE showed a comparable OS, TTP, and TTIP and a better safety profile.